PATH | VRL
Menu

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. This article, published in PLoS Neglected Tropical Diseases, reports the results of a study assessing a P. vivax malaria vaccine candidate. The vaccine was shown to be well tolerated, immunogenic, and volunteers generated immune responses to the vaccine antigen, but vaccination did not induce protection. This trial is significant in that it is the first to assess the efficacy of a P. vivax vaccine candidate through use of a controlled human malaria infection model. The availability of this model will accelerate the process of P. vivax vaccine development.

Author: Bennett JW, Yadava A, Tosh D, et al.

Published: 2016

» Visit web page (English)

(Located at journals.plos.org)

Citation: Bennett JW, Yadava A, Tosh D, et al. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Neglected Tropical Diseases. 2016;10(2):e0004423.

Resource types: Peer-reviewed journal

Diseases/vaccines: Malaria

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global